Aliskiren/amlodipine

Aliskiren/amlodipine
Combination of
Aliskiren	Renin inhibitor
Amlodipine	Calcium channel blocker (dihydropyridine)
Clinical data
Trade names	Tekamlo, Rasilamlo
AHFS/Drugs.com	Professional Drug Facts
License data	US FDA: Tekamlo;
Pregnancy; category	C in first trimester;; D in second and third trimesters;
Routes of; administration	By mouth
ATC code	C09XA53 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
CAS Number	1416233-20-9 ;
	(what is this?) (verify)

The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own,^[1] with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.^[2]

References

^ Pfeiffer D, Rennie N, Papst CC, Zhang J (November 2012). "Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥". Current Vascular Pharmacology. 10 (6): 773–80. doi:10.2174/157016112803520945. PMID 22303911.
^ Axthelm C, Sieder C, Meister F, Kaiser E (January 2012). "Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg". Current Medical Research and Opinion. 28 (1): 69–78. doi:10.1185/03007995.2011.637914. PMID 22117838. S2CID 25693979.

External links

"Aliskiren mixture with amlodipine". Drug Information Portal. U.S. National Library of Medicine.

Lua error in mw.title.lua at line 346: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[PfeifferRennie2012-1] Pfeiffer D, Rennie N, Papst CC, Zhang J (November 2012). "Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥". Current Vascular Pharmacology. 10 (6): 773–80. doi:10.2174/157016112803520945. PMID 22303911.

[AxthelmSieder2011-2] Axthelm C, Sieder C, Meister F, Kaiser E (January 2012). "Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg". Current Medical Research and Opinion. 28 (1): 69–78. doi:10.1185/03007995.2011.637914. PMID 22117838. S2CID 25693979.

[1]

[2]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril^# (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +amlodipine and HCT, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

References

Further reading

External links